Clinical Trials Logo

Chronic Lymphocytic Leukemia clinical trials

View clinical trials related to Chronic Lymphocytic Leukemia.

Filter by:

NCT ID: NCT01696461 Completed - Clinical trials for Chronic Lymphocytic Leukemia

A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor

Start date: May 2013
Phase: Phase 2
Study type: Interventional

This is a Phase II, open-label, two strata, multicenter, prospective study of plerixafor-mobilized HLA-identical sibling allografts in recipients with hematological malignancies. This study will establish the safety and efficacy of subcutaneous plerixafor for this purpose.

NCT ID: NCT01682616 Completed - Clinical trials for Chronic Lymphocytic Leukemia

A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Start date: July 25, 2012
Phase: Phase 1
Study type: Interventional

This is a Phase 1b, open-label, multicenter study evaluating the safety and tolerability of ABT-199 in combination with rituximab in up to 50 subjects with Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma. The primary objectives of this study are to assess the safety profile, to determine the maximum tolerated dose and establish the Recommended Phase Two Dose of ABT-199 when administered in combination with rituximab. The dose escalation portion of the study will include approximately 30 subjects. Once the recommended phase two dose and schedule have been determined, up to 20 additional subjects will be enrolled in an expanded safety portion of the study. Subjects who meet criteria for CR, CRi, or MRD-negative PR during the study may discontinue ABT 199. If disease progression occurs, as defined by iwCLL NCI/WG criteria for tumor response, or MRD progression, subjects may re-initiate ABT-199.

NCT ID: NCT01681563 Completed - Clinical trials for Chronic Lymphocytic Leukemia

Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia

Start date: September 2011
Phase: Phase 2
Study type: Interventional

This is a phase II multicenter, non-comparative, open label study in older previously untreated Chronic Lymphocytic Leukaemia patients, requiring therapy, aimed at defining the efficacy profile (ORR, CRR and TTP) of pentostatin and cyclophosphamide given in combination with Ofatumumab (PCO).

NCT ID: NCT01671904 Completed - Clinical trials for Chronic Lymphocytic Leukemia

A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Start date: January 13, 2014
Phase: Phase 1
Study type: Interventional

This multi-center, open-label, dose-finding study will evaluate the safety and pharmacokinetics of venetoclax (GDC-0199, ABT-199) administered in combination with bendamustine and rituximab (BR) (MabThera/Rituxan) or bendamustine and obinutuzumab (BG) to participants with first-line (1L)/previously untreated or relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). The study will explore two venetoclax combination regimens in participants with 1L CLL: BR+venetolax (V) and BG+V. Participants with R/R CLL will be administered BR+V.

NCT ID: NCT01670812 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Trial of FFP+HDMP+Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia

Start date: January 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate efficacy and safety of fresh frozen plasma(FFP), high dose methylprednisolone(HDMP) and rituximab for ultra-high risk chronic lymphocytic leukemia.

NCT ID: NCT01659047 Withdrawn - Clinical trials for Chronic Lymphocytic Leukemia

A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia

Start date: August 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the effect of GS-1101 on the onset, magnitude, and duration of tumor control

NCT ID: NCT01659021 Terminated - Clinical trials for Chronic Lymphocytic Leukemia

Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia

Start date: December 4, 2012
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate the effect of the addition of idelalisib to ofatumumab on progression-free survival (PFS) in participants with previously treated chronic lymphocytic leukemia (CLL).

NCT ID: NCT01657955 Recruiting - Leukemia Clinical Trials

Bendamustine Hydrochloride Injection for Previously Untreated Chronic Lymphocytic Leukemia

CLL
Start date: January 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether bendamustine is effective in the treatment of initial treatment of Chronic Lymphocytic Leukemia (CLL).

NCT ID: NCT01650727 Completed - Clinical trials for Chronic Lymphocytic Leukemia

A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974)

Start date: October 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the maximum-tolerated dose (MTD) of dinaciclib therapy in combination with rituximab in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

NCT ID: NCT01649791 Completed - Clinical trials for Chronic Lymphocytic Leukemia

Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia

Start date: January 2010
Phase: N/A
Study type: Interventional

This clinical trial studies lenalidomide as chemoprevention in treating patients with high-risk, early stage B-cell chronic lymphocytic leukemia (B-CLL). Chemoprevention is the use of certain drugs to keep cancer from forming. The use of lenalidomide may slow disease progression in patients with early stage B-cell chronic lymphocytic leukemia